A user discusses a topical treatment combining Minoxidil, Betamethasone Valerate, Canrenone, Finasteride, and Dutasteride for hair loss. The treatment is RX-only and provided by a dermatologist.
A 42-year-old is using a topical solution with 5% minoxidil and 0.1% finasteride, along with weekly microneedling, for hair regrowth without side effects. The product used is Tugain for men by Cipla, an Indian brand.
A new topical treatment, TH07, combining finasteride, latanoprost, and minoxidil, is entering phase III trials with promising early results. Some users express skepticism, noting the treatment uses existing products.
A user is considering ordering topical finasteride with castor and rosemary oil from a Turkish pharmacy. They are debating whether to include the oils or use only PG and ethanol as the carrier.
The conversation discusses the potential benefits of creating a hydrophobic version of finasteride to reduce systemic side effects while maintaining scalp health. It compares this idea to fluridil, which is designed to be hydrophobic and has less systemic absorption.
PP405 shows promise for hair follicle reactivation with minimal side effects. Users recommend continuing Minoxidil and Finasteride until more results are confirmed.
The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.
The conversation is about a user's hair regrowth progress using topical Minoxidil 5%, a derma roller, Foligain Trioxidil shampoo, and various supplements like zinc, selenium, magnesium, B6, B7, saw palmetto, and D3 + K2. The user is seeking finasteride but faces prescription challenges in Italy.
The user had a failed hair transplant in 2018, didn't use medication, and experienced severe depression from further hair loss. They started treatment in 2022 with 0.5mg daily finasteride, 2.5mg oral minoxidil, 1ml daily topical minoxidil, and are considering low dose RU58841 and dermarolling.
The conversation discusses how the absorption rate of topical finasteride varies and is not equivalent to its oral form, with only a small percentage reaching the scalp. It also mentions that minoxidil in high concentrations is used topically because only a small amount is absorbed.
Microneedling daily at 0.3mm combined with topical finasteride and minoxidil is effective for hair thickening, with added benefits from near-infrared therapy. The approach may not improve the front hairline, and deeper microneedling is done monthly for better results.
The user experienced some hair regrowth using twice daily topical 5% minoxidil and once daily oral 1mg finasteride, along with dermarolling. They plan to continue this regimen for at least two years and may try additional treatments if needed.
The user has been using a combination of 0.3% topical finasteride, minoxidil, ketoconazole, and microneedling once a week for two months with positive results and no side effects. They apply the treatment daily using a spray and have short hair, which makes application easier.
The conversation discusses the delay in bringing FAK inhibitors and Stanford's hydrogel to market for hair transplants, with a preference for FAK inhibitors over Verteporfin due to their superior potential in preventing scarring. The user expresses frustration over the slow progress and hopes for faster development by companies like FAKnostics.
The conversation is about using Verteporfin with microneedling as a potential hair loss treatment that may regenerate hair follicles with minimal scarring. There are concerns about the optimal dosage and the DHT sensitivity of the new follicles.
The conversation discusses sourcing topical dutasteride for hair loss treatment, with mentions of Dr. Mwamba's products and Farmacia Prati as potential suppliers. Additional treatments like topical tocotrienols and botox are suggested as extensions to the regimen.
PP405 is discussed as a potential adjunct therapy for hair loss, with skepticism about its effectiveness and trial results. Users mention combining it with finasteride and minoxidil for better results, while others debate the root causes of hair loss and the limitations of current treatments.
Low-dose Dutasteride, used 2-3 times a week, is as effective as daily Finasteride for hair loss with fewer side effects. Users report increased libido and better results with Dutasteride compared to Finasteride.
The user has been using finasteride, minoxidil, microneedling, PRP, and ProCell therapy for hair loss but sees no progress after nine months. They are considering switching to dutasteride and possibly a hair transplant, with suggestions to add oral minoxidil.
The conversation discusses hair loss treatments, focusing on finasteride, minoxidil, and other options like PRP and ketoconazole. It highlights the importance of asking specific questions during a dermatology visit to determine the cause of hair loss and appropriate treatments.
Higher doses of dutasteride, like 2.5 mg, may offer more hair growth than 0.5 mg, but the difference is not significant for most people. Many users find 0.5 mg effective, and increasing the dose is often unnecessary unless experiencing severe hair loss.
0.5mg dutasteride reduces scalp DHT more than 1mg finasteride, leading to better hair regrowth results. Users report significant improvement with dutasteride compared to finasteride.
Creatine may increase scalp DHT without affecting serum DHT, potentially speeding up male pattern baldness (MPB) for those genetically prone. Treatments mentioned include Minoxidil, finasteride, and RU58841.
A user added sandalore to minoxidil for hair loss, observing some vellus hair growth and less scalp inflammation. Others tried sandalore with mixed results, discussing dosage and effectiveness compared to minoxidil and finasteride.
The conversation discusses the potential of Verteporfin, an FDA-approved drug, for hair loss treatment, particularly in combination with microneedling or PRP. Users express hope and curiosity about its application, while some remain cautious due to the need for more extensive testing.
The post discusses the use of latanoprost foam for hair growth, with the user expressing concerns about its efficiency and safety. The user is currently using topical dutasteride, which maintains their hair but doesn't promote regrowth, and is seeking a product that doesn't affect hormone levels.
The user struggles to cover their entire scalp with 1 ml of RU58841 while using dutasteride and oral minoxidil for hair loss. Suggestions include using a syringe for precise application, applying twice daily, and considering the use of more than 1 ml to ensure full coverage.
Botox injections may be more effective than finasteride for hair growth by reducing scalp tension. The discussion also suggests choosing FUE over FUT due to potential loss of scalp elasticity with FUT.
A user is seeking advice on a new topical hair loss treatment containing Minoxidil 3%, Finasteride 0.3%, Progesterone 1%, Hydrocortisone butyrate 0.1%, and Ketoconazole 0.5%. They are concerned about the systemic absorption of Finasteride and plan to do blood tests and a spermiogram before starting.
A trans woman is using 10 mg oral minoxidil, dutasteride, and estradiol for hair regrowth and is also doing dermastamping despite the pain. Users discuss the benefits of dermastamping for serum absorption and hair follicle stimulation, with some expressing surprise at the high minoxidil dosage.